Manipulation? Maybe not? The below post, in a nutshell,

New Post Public Reply Private Reply Replies (4) Message Board
jconst345 HCIT #64927
967
Manipulation? Maybe not? The below post, in a nutshell, elaborates on my thought that there is NO manipulation, just retail traders doing their thing. That’s your “unknown enemy” that behaves so irrationally that you can’t possibly assign the least bit of logic to it which actually explains things perfectly.

Read further for my rationale:

-manipulators end goal is financial gain, who are the possibilities? Big pharma, financiers, traders

Big pharma: Takeover CYDY; Negotiate better partnership terms; Avoid revenue losses on existing/upcoming pipelines

Financiers: Better terms for next financing round; Lower conversion price on previous round

Traders: short term profits

Weapons available: Shorting the stock into oblivion. Selling existing shares accumulated in the past.

Risk: Stock rips in their face as the pockets of the collective investment community eventually overpowers theirs given possible high visibility and government (OWS) support. Life and death here, if we literally save lives, we won’t fly under the radar, the worlds eyes will be on us. Eventually the manipulator will need to dial it in.

Breaking it down further against manipulation:
Big pharma - NP won’t be doing anything until S/c is done or long haulers is done or HIV PDUFA outcome is known. Assuming any of those succeed, he won’t be selling the firm AND his negotiating position is worlds better regardless of stock price AND the jig is over for Big pharma losing revs, because they will. So if big pharma manipulation is basically futile, then who?

Financiers - let’s assume you need to be at least 1/3 of the volume to hold a stock down. This has been going on for weeks if not months. The amount of $$ to risk to do that likely exceeds any potential gain from a next round of financing at these prices. The potential for the stock to go vertical overnight on an EUA or OWS or approval announcement is high. I put low probability that Iliad or Paulson are keeping this down. They will do just fine if the stock rips, no need to potentially shoot their own foot.

Traders - we already saw this at $10. It worked. They made $$. But that was low hanging fruit. The fruit is not low hanging at $3 or $2. It just isn’t.

Yet despite the above, the stock keeps falling. What gives?

I’ll posit the following - 43,000 retail traders is what gives. They are the weakest hands out there. They whip this around, panic and hope and fear and greed and fast money and Robinhood and etc. They have thin pockets, 5,000 shares, 20,000 shares whatever it is per person. It adds up quickly when multiplied by 43,000. Cash strapped, trigger happy, unemployed possibly, whittling retirement accounts... they can make charts look crazy in both directions.

There are virtually no institutional holders here. It’s an OTC stock with just hopes and dreams right now. Institutional big money would much rather buy certainty than uncertainty. Hence the mystery billionaire saying they would personally step in ASSUMING APPROVAL. A billionaire can easily get involved at $10 or $15 per share with low risk than $2 per share with high risk (in their minds, not mine...).

So I take the no manipulation standpoint at this time as I just don’t see a successful endgame for any of the players given what we know about NP and the probability of the success of LL and the high visibility of Covid across the entire planet. I think it’s all retail.

You know what that does? It comforts the heck out of me as I wrap up my Lagavulin. Once smart $$ is locked in, the trend will permanently reverse.

Happy to have well thought out holes poked into the above.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 2

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 1

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 6

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 4

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 4

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 3

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading

Top 5 Most Recently Viewed Articles

CoreWeave Gains Amid NVIDIA Partnership, Faces Skepticism

Updated Category News Views 205

CoreWeave Stock Surges with NVIDIA Agreement Shares of CoreWeave, Inc. experienced a notable increase recently following the announcement of a significant partnership with NVIDIA Corp. This new agreement, valued at an initial $6.3 billion, allows NVIDIA to purchase any excess cloud computing capacity that CoreWeave may have available. The partnership is expected to last...

Continue Reading
Coty's Preliminary Q1 Review: Sales Growth Insights and Strategy

Updated Category News Views 65

Coty Inc. Preliminary Q1 Overview Coty Inc. (NYSE: COTY) has recently reported its preliminary numbers for the first quarter, revealing some intriguing insights into its sales growth. The company experienced a modest increase of approximately 4%-5% on a like-for-like basis, which unfortunately fell short of their previous estimate of 6%. This slight underperformance has...

Continue Reading
Uncle Funky's Daughter Launches Innovative Hair Mousse

Updated Category News Views 420

Introducing Soul Bounce Texture Defining Mousse Uncle Funky's Daughter, a celebrated minority-owned hair care brand, has introduced an innovative product known as Soul Bounce Texture Defining Mousse. This exciting addition aims to elevate the hairstyling routine for individuals with textured hair, offering a solution that balances definition, volume, and health. The...

Continue Reading
Arconic Corporation Faces Class Action Lawsuit Over Securities Losses

Updated Category News Views 205

Arconic Corporation's Legal Challenges for Investors In the ever-evolving landscape of corporate governance, Arconic Corporation is currently facing serious legal scrutiny. Investors are being made aware that a class action lawsuit has been initiated against the company, highlighting concerns over significant losses among shareholders. Class Action Overview This lawsuit...

Continue Reading
Key Insights on Centene Corporation Class Action for Investors

Updated Category News Views 131

Understanding the Centene Corporation Class Action Lawsuit In recent developments, Centene Corporation (NYSE: CNC) has found itself at the center of a class action lawsuit. This legal proceeding has garnered attention due to allegations that Centene and its senior executives may have violated federal securities laws. Legal representation is being offered by a leading firm...

Continue Reading